Bone Marrow Transplantation最新文献

{"title":"Real-world outcomes of haplo-HSCT with post-transplant cyclophosphamide in pediatric hematologic malignancies: a study on behalf of SFGM-TC and SFCE","authors":"Charlotte Calvo, Cléo Hautefeuille, Loïc Vasseur, Florian Chevillon, Charlotte Nazon, Benedicte Bruno, Marc Ansari, Arthur Sterin, Anne Sirvent, Audrey Grain, Marie Angoso, Virginie Gandemer, Pascale Schneider, Carine Halfon-Domenech, Pierre-Simon Rohrlich, Cécile Pochon, Catherine Paillard, Stephanie Nguyen Quoc, Nicole Raus, Marion Strullu, Françoise Méchinaud, Nathalie Dhedin, Jean-Hugues Dalle","doi":"10.1038/s41409-025-02584-4","DOIUrl":"10.1038/s41409-025-02584-4","url":null,"abstract":"","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":"60 6","pages":"917-920"},"PeriodicalIF":4.5,"publicationDate":"2025-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143961440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-T lymphocyte globulin plus posttransplant cyclophosphamide 25 mg/kg versus posttransplant cyclophosphamide 50 mg/kg in patients with acute leukemias","authors":"Abdullah Karakus, Tayfur Toptas, Mehmet Sinan Dal, Ali Durdu, Ugur Hatipoglu, Merve Apaydin Kayer, Ipek Yonal Hindilerden, Tarik Onur Tiryaki, Dicle Iskender, Bahar Uncu Ulu, Tugce Nur Yigenoglu, Mehmet Ali Erkurt, Turgay Ulas, Fevzi Altuntas","doi":"10.1038/s41409-025-02564-8","DOIUrl":"10.1038/s41409-025-02564-8","url":null,"abstract":"In this study, we aimed to compare the engraftment days, graft-versus-host disease (GVHD) development, relapse and overall survival rates in patients using myeloablative/reduced intensity conditioning regimens with posttransplant cyclophosphamide (PTCy) 25 mg/kg x2 with Anti-T lymphocyte Globulin (ATLG) (n = 29) and PTCy 50 mg/kg x2 doses (n = 41) in patients with acute leukemias. Matched related, matched unrelated, 1 mismatched unrelated, and haploidentical donors were selected for the patients. Platelet (median 11 vs 17 days) and neutrophil (median 14 vs 15 days) engraftment times were shorter in ATLG+ PTCy25 treated patients (both p < 0.05); veno-occlusive disease rates, graft failure and poor graft functions were similar between the two approaches (all p > 0.05); cumulative incidences of grade II-IV aGVHD at +100 days, grade III-IV aGVHD at +100 days, and grade II-IV cGVHD at 1-year were comparable between ATLG+PTCy25 and PTCy50 groups (all p > 0.05). Cumulative incidences of relapse and non-relapse mortality at 1-year were similar in two cohorts (both p > 0.05). PTCy50 was associated with a statistically significant benefit in terms of GVHD-free/relapse-free survival (GRFS) at 1-year (p = 0.03). Median GRFS was 115 (95% CI: 42–214) days and 248 (95% CI: 151-not reached) days, respectively [HR was 0.51 (0.28–0.95), p = 0.03; GRFS at 1-year was 20.7% vs 44.3%, respectively]. However, the groups were comparable in terms of PFS and OS. Median PFS was 332 days (95% CI: 182 days-not reached) for ATLG+PTCy25 group. It was not reached (95% CI: 210 days-not reached) for the patients who received PTCy50. Median OS was not reached in either ATLG+PTCy25 (95% CI: 191 days-not reached) or PTCy50 groups (Log rank = 0.42). Our study showed that lowering PTCy dose with ATLG seems to accelerate platelet and neutrophil engraftment rates; confers similar survival and relapse rates, similar acute and chronic GVHD frequency despite increased GRFS at 1-year.","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":"60 6","pages":"864-872"},"PeriodicalIF":4.5,"publicationDate":"2025-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41409-025-02564-8.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143958462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes in allogeneic hematopoietic stem cell transplantation for Fanconi anemia","authors":"M. Gonzalez Vicent, A. Peretó, J. Zubicaray, B. Molina, S. Vinagre, E. Sebastián, J. Iriondo, A. Castillo, L. Abad, A. Sanz, G. Lopez de Hontanar, M. Ramirez, J. Sevilla, M. A. Diaz","doi":"10.1038/s41409-025-02591-5","DOIUrl":"10.1038/s41409-025-02591-5","url":null,"abstract":"","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":"60 6","pages":"914-916"},"PeriodicalIF":4.5,"publicationDate":"2025-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143962141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Food insecurity prior to hematopoietic stem cell transplant is associated with malnutrition and worse outcomes","authors":"Matthew A. Bergens, Yen P. Lowder, Yan Li, Ernaya J. Johnson, Hilary M. Winthrop, Amy T. Bush, Angela Xiong, Lauren Hill, Isabella Gorski, Bethany Weaver, S. Yousuf Zafar, Edwin P. Alyea, Nelson J. Chao, Taewoong Choi, Cristina Gasparetto, Sanghee Hong, Mitchel E. Horwitz, Chenyu Lin, Gwynn D. Long, Richard D. Lopez, Sendhilnathan Ramalingam, Stefanie Sarantopoulos, Keith M. Sullivan, Anthony D. Sung","doi":"10.1038/s41409-025-02587-1","DOIUrl":"10.1038/s41409-025-02587-1","url":null,"abstract":"Food insecurity (FI), defined as the lack of continuous access to adequate food, affects 17–55% of cancer patients. Effects may be exacerbated in hematopoietic stem cell transplant (HSCT) patients, who face nutritional challenges due to treatment side effects, leading to weight loss and malnutrition. We hypothesize that pre-HSCT FI increases the risk of malnutrition, requiring nutrition support, and adverse psychosocial outcomes. Between February 2018 and August 2022, 284 patients were screened before HSCT for FI. 71 (25%) were excluded due to missing data. Of the remaining 213, 20 (9.4%) reported pre-HSCT FI. Patients with FI were more likely to develop malnutrition during HSCT (70% vs. 45.1%, p = 0.034) and need total parenteral nutrition compared to those without FI (65% vs. 34.2%, p = 0.013). Patients with FI also were more likely to screen positive for depression (40% vs. 10.4%, p = 0.002) and financial toxicity (75% vs. 25%, p < 0.001). There were no significant differences in survival or other secondary outcomes. Our study demonstrates that pre-HSCT FI significantly increases likelihood of malnutrition, the need for total parenteral nutrition, and adverse psychosocial outcomes in HSCT patients. These findings highlight the critical importance of early identification and interventions to address FI as part of comprehensive cancer care.","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":"60 6","pages":"857-863"},"PeriodicalIF":4.5,"publicationDate":"2025-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143962282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Barriers to allogeneic stem cell transplantation in responding patients with TP53-mutated acute myeloid leukemia","authors":"Jayastu Senapati, Guillermo Garcia-Manero, Courtney D. DiNardo, Indraneel Deshmukh, Gautam Borthakur, Tapan M. Kadia, Elias Jabbour, Nicholas J. Short, Hussein A. Abbas, Naveen Pemmaraju, Nitin Jain, Fadi G. Haddad, Ghayas C. Issa, Abhishek Maiti, Elizabeth Shpall, Uday Popat, Sanam Loghavi, Guilin Tang, Musa Yilmaz, Yesid Alvarado, Guillermo Montalban-Bravo, Farhad Ravandi, Hagop M. Kantarjian, Naval G. Daver","doi":"10.1038/s41409-025-02590-6","DOIUrl":"10.1038/s41409-025-02590-6","url":null,"abstract":"","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":"60 6","pages":"910-913"},"PeriodicalIF":4.5,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143973732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of center volume on outcomes in allogeneic hematopoietic cell transplantation for children","authors":"Motohiro Kato, Hideki Nakashone, Keitaro Matsuo, Yuri Ito, Atsumi Yanagisawa, Marie Ohbiki, Ken Tabuchi, Tatsuo Ichinohe, Yoshiko Hashii, Junya Kanda, Hideki Goto, Koji Kato, Makoto Yoshimitsu, Atsushi Sato, Moeko Hino, Kimikazu Matsumoto, Kimikazu Yakushijin, Yoshiko Atsuta, Takahiro Fukuda","doi":"10.1038/s41409-025-02569-3","DOIUrl":"10.1038/s41409-025-02569-3","url":null,"abstract":"The impact of center volume on outcomes in pediatric hematopoietic cell transplantation (HCT) is not well established. We retrospectively analyzed data from a nationwide registry, including 6966 pediatric patients who underwent their first allogeneic HCT at 123 centers in Japan between 2001 and 2020. Centers were categorized by transplant volume as low volume centers (C1, the smallest number of transplantation), medium-low volume centers (C2), medium-high volume centers (C3), and high volume centers (C4, the greatest number of transplantation), and outcomes were compared across these categories. The analysis revealed no statistically significant differences in HCT outcomes among center categories. The 5-year OS by center category was 66.8% (95% CI 64.4–69.0%) for C1, 66.8% (95% CI 64.5–69.0%) for C2, 67.9% (95% CI 65.6–70.2%) for C3, and 68.3% (95% CI 65.9–70.6%) for C4. These results were consistent even when analysis was restricted to malignant and nonmalignant diseases. Our findings suggest that, unlike in adult HCT, outcomes for pediatric HCT are not significantly affected by center volume. These results indicate the consistent quality of care across centers, supporting the accessibility of HCT at various institutions for pediatric patients.","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":"60 6","pages":"851-856"},"PeriodicalIF":4.5,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41409-025-02569-3.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143973839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Less frequent complications following CAR T-cell therapies: hemophagocytic lymphohistiocytosis, graft-versus-host disease, thrombotic microangiopathy, coagulation disorders and secondary malignancies: best practice recommendations from the EBMT Practice Harmonization and Guidelines Committee","authors":"Guillermo Ortí, Guillaume Dachy, Charlotte E. Graham, Zinaida Peric, Ana Alarcon, Francesca del Bufalo, Matteo Doglio, Jan-Inge Henter, Claire Roddie, Orla Stewart, W.C.J. Van de Donk, Roser Velasco, Mahmoud Aljurf, Annalisa Ruggeri, Francesco Onida, Isabel Sánchez-Ortega, Ibrahim Yakoub-Agha, Olaf Penack","doi":"10.1038/s41409-025-02567-5","DOIUrl":"10.1038/s41409-025-02567-5","url":null,"abstract":"CAR T-cell therapies have revolutionized the treatment of hematologic malignancies; however, alongside the well-known complications of cytokine release syndrome (CRS), neurotoxicity, immune effector cell–associated hematotoxicity (ICAHT), and infections, other non-classical toxicities are emerging. This review, developed by the EBMT Practice Harmonization and Guidelines Committee, addresses the management of other critical post-CAR T-cell complications including hemophagocytic lymphohistiocytosis (HLH), graft-versus-host disease (GvHD), thrombotic microangiopathy (TMA), coagulation disorders and secondary malignancies. These complications, though less frequent, present a significant challenge, often contributing to morbidity and mortality with no standardized management protocols. This review provides best practice recommendations for early identification, risk mitigation, and therapeutic interventions, supported by limited but emerging clinical evidence. Comprehensive expert guidance is essential for optimal management of these under-explored toxicities following CAR T-cell therapies.","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":"60 6","pages":"751-758"},"PeriodicalIF":4.5,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41409-025-02567-5.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143983505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"GvHD prophylaxis with tacrolimus, sirolimus, and mycophenolate mofetil after reduced intensity conditioning hematopoietic stem cell allogeneic transplantation","authors":"L. Lopez-Corral, C. Blázquez-Goñi, E. Pérez-López, FM Martín-Domínguez, A. Cabero Martínez, N. Rodríguez-Torres, M. Cabrero, I. Espigado-Tocino, AA Martín López, R. Parody-Porras, M. Baile González, T. Caballero-Velázquez, M. Cortés-Rodríguez, E. Soria-Saldise, A. Avendaño Pita, P. Alcalde-Mellado, A. García Bacelar, E. Rodríguez-Arbolí, M. López Parra, JF Falantes-González, A. Navarro-Bailón, L. Vázquez López, V. Escamilla-Gómez, F. Sánchez-Guijo, JA Pérez-Simón","doi":"10.1038/s41409-025-02562-w","DOIUrl":"10.1038/s41409-025-02562-w","url":null,"abstract":"We present the largest prospective real-world experience in 159 patients who received the triple combination of tacrolimus/sirolimus/mycophenolate mofetil after reduced intensity conditioning allogeneic hematopoietic stem cell transplantation (RIC-alloHSCT) from matched-related (MRD), matched-unrelated (MUD) or mismatched-unrelated donors (MMURD). Despite the high-risk and elderly population, non-relapse mortality (NRM) at day +100 and 1 year was 5.1% and 8.6%. Grades 2-4 and 3-4 acute Graft-versus-host disease (GvHD) at day +180 was 30.3% and 13%, respectively. Chronic GvHD at 1 and 3 years was 23.2% and 41% and for moderate/severe was 13.2% and 26.6%, respectively. With a median follow-up of 20 months, the 1- and 3-year progression-free survival was 60% and 49%, the GvHD-free relapse-free survival was 44% and 32%, and the overall survival was 70.3% and 61%, respectively, for the entire cohort. Patients receiving allo-HSCT from MMURD showed a higher incidence of aGvHD with impact on survival endpoints. GvHD prophylaxis with the triple-drug combination tacrolimus/sirolimus/mycophenolate mofetil showed excellent results in terms of NRM, GvHD and survival in a high-risk, frail and elderly population in the context of RIC-HSCT from MRD and MUD. The subgroup of patients receiving RIC-HSCT from MMURD might probably benefit from other prophylaxis strategies.","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":"60 6","pages":"832-840"},"PeriodicalIF":4.5,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41409-025-02562-w.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143810475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world outcomes of brentuximab vedotin as consolidation therapy after autologous stem cell transplantation in relapsed/refractory Hodgkin lymphoma: A systematic review and meta-analysis","authors":"Anna Sureda, Astrid Pavlovsky, Dalah Haidar, Fjoralba Kristo, Vanessa Stache, Athanasios Zomas","doi":"10.1038/s41409-025-02557-7","DOIUrl":"10.1038/s41409-025-02557-7","url":null,"abstract":"Brentuximab vedotin (BV) as post-autologous stem cell transplantation (ASCT) consolidation was shown to reduce the relapse risk among high-risk patients with relapsed/refractory Hodgkin lymphoma (RRHL) in the clinical trial setting. This systematic review and meta-analysis characterizes real-world evidence (RWE) on the effectiveness and safety of BV as post-ASCT consolidation in 1504 adult and pediatric patients with RRHL from 23 studies across 17 countries. A random-effects model yielded pooled progression-free survival (PFS) and overall survival rates (OS); PFS: 2-year, 74.2%; 5-year, 65.8%; OS: 2-year, 95.8%; 5-year, 91.9%. The most common any-grade adverse events were neuropathy (34.2%) and neutropenia (20.2%). Despite heterogeneity in populations and outcomes, this analysis utilizing real-world data corroborates the efficacy and safety of BV as post-ASCT consolidation in RRHL reported in the experimental arm of the Phase III AETHERA trial. The favorable PFS results in cases exposed to BV prior to ASCT indicate the value of BV in controlling Hodgkin lymphoma (HL) in the salvage setting. Continued research is essential to refine BV treatment strategies amid the evolving treatment landscape.","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":"60 6","pages":"820-831"},"PeriodicalIF":4.5,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41409-025-02557-7.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143810379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bone marrow versus peripheral blood stem cells as the graft source for allogeneic transplantation from HLA-matched relative donors in adult T-cell leukemia/lymphoma: A nationwide retrospective study by the ATL working group of the Japanese Society for Transplantation and Cellular Therapy","authors":"Hidehiro Itonaga, Takuya Fukushima, Koji Kato, Hiroyuki Muranushi, Masahito Tokunaga, Takahiro Fukuda, Toshiro Kawakita, Takeharu Kato, Yasuo Mori, Sawako Nakachi, Youko Suehiro, Takuro Kuriyama, Machiko Fujioka, Makoto Onizuka, Tatsuo Ichinohe, Marie Ohbiki, Yoshiko Atsuta, Shigeo Fuji, Makoto Yoshimitsu","doi":"10.1038/s41409-025-02563-9","DOIUrl":"10.1038/s41409-025-02563-9","url":null,"abstract":"","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":"60 6","pages":"906-909"},"PeriodicalIF":4.5,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143810467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}